What are the most important drivers of cost in AML and how can they be ameliorated?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Gunnar Juliusson, Lund University, Lund, SE. We asked: What are the most important drivers of cost in acute myeloid leukemia and how can they be ameliorated?

Gunner Juliusson discusses the results from his study, where all cost associated with AML diagnosis were evaluated, such as treatment, hospitalization, work and general livelihood. He explained treatment for younger patients are typically more costly because they are eligible for a more dynamic treatment pathway, compared to older patients with AML.